Cited by 282Smoking Behavior and CessationMonoclonal and Polyclonal Antibodies ResearchSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial

Open access

Cornuz, Jacques, Zwahlen, Susanne, Jungi, Walter Felix, Osterwalder, Joseph, Klingler, Karl, van Melle, Guy, Bangala, Yolande, Guessous, Idris, Müller, Philipp, Willers, Jörg, Maurer, Patrik, Bachmann, Martin F., Cerny, Thomas·2008·PLoS ONE

DOI 10.1371/journal.pone.0002547PMC PMC2432028

Open this paper in CoChat — free account

Abstract

BACKGROUND: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period. METHODOLOGY/PRINCIPAL FINDINGS: 229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Qbeta (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012). CONCLUSIONS: Whereas Nicotine-Qbeta did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction. TRIAL REGISTRATION: Swiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0002547

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Harper, D. M., Franco, E. L., Wheeler, C. M., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B. L., Naud, P., de Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,639
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings
Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188
The Influence of Antigen Organization on B Cell Responsiveness
Bachmann, M. F., Rohrer, U. H., Kündig, T. M., Bürki, K., Hengartner, H., & Zinkernagel, R. M. (1993) · Science · doi:10.1126/science.8248784 · Cited by 718
Antidepressants for smoking cessation
Hughes, J., Stead, L., & Lancaster, T. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031 · Cited by 683
Development and validation of the Wisconsin Smoking Withdrawal Scale.
Welsch, S. K., Smith, S. S., Wetter, D. W., Jorenby, D. E., Fiore, M. C., & Baker, T. B. (1999) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.7.4.354 · Cited by 308
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity
Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279
Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial
Harper, D. M., Franco, E. L., Wheeler, C. M., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B. L., Naud, P., Decarvalho, N. S., et al. (2005) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000154423.27940.68 · Cited by 247

Flagged first, then by citations

Show all 28 references

Sorted by citations

Items 101–200 of 282

Targeting nicotine addiction: the possibility of a therapeutic vaccine
Escobar‐Chávez, J. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s10033 · Cited by 35
Modulation of benzo[a]pyrene induced neurotoxicity in female mice actively immunized with a B[a]P–diphtheria toxoid conjugate
Schellenberger, M. T., Grova, N., Farinelle, S., Willième, S., Schroeder, H., & Muller, C. P. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.05.007 · Cited by 33
Animal Models and the Development of Vaccines to Treat Substance Use Disorders
Ohia-Nwoko, O., Kosten, T. A., & Haile, C. N. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.02.009 · Cited by 33
Stealing a March in the 21st Century: Accelerating Progress in the 100-Year War Against Tobacco Addiction in the United States
Fiore, M. C., & Baker, T. B. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.154559 · Cited by 33
Immunization against angiotensins for the treatment of hypertension
Maurer, P., & Bachmann, M. F. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.06.003 · Cited by 32
A Conjugate Vaccine Attenuates Morphine- and Heroin-Induced Behavior in Rats
Li, Q., Sun, C., Luo, Y.-X., Xue, Y.-X., Meng, S., Xu, L., Chen, N., Deng, J.-H., Zhai, H., Kosten, T. R., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu093 · Cited by 32
Smoking cessation-recent advances
McNeil, J. J., Piccenna, L., & Ioannides-Demos, L. L. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6246-8 · Cited by 31
Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization
Zhao, Z., Hu, Y. Y., Harmon, T. M., Pentel, P. R., Ehrich, M. F., & Zhang, C. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.031 · Cited by 31
Is immunotherapy an opportunity for effective treatment of drug addiction?
Zalewska-Kaszubska, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.079 · Cited by 31
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform
O’Rourke, J. P., Peabody, D. S., & Chackerian, B. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.005 · Cited by 30
Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse
Brimijoin, S., Shen, X., Orson, F. M., & Kosten, T. R. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.1 · Cited by 30
Current status of vaccines for substance use disorders: A brief review of human studies
Truong, T. T., & Kosten, T. R. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120098 · Cited by 30
Combined active and passive immunization against nicotine: Minimizing monoclonal antibody requirements using a target antibody concentration strategy
Cornish, K. E., Harris, A. C., LeSage, M. G., Keyler, D. E., Burroughs, D., Earley, C. A., & Pentel, P. R. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.07.009 · Cited by 30
Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines
Aves, K.-L., Goksøyr, L., & Sander, A. F. (2020) · Viruses · doi:10.3390/v12020185 · Cited by 29
Virus-Like Particles, a Versatile Subunit Vaccine Platform
Donaldson, B., Al-Barwani, F., Young, V., Scullion, S., Ward, V., & Young, S. (2014) · Subunit Vaccine Delivery · doi:10.1007/978-1-4939-1417-3_9 · Cited by 33
Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine
Skibinski, D. A. G., Hanson, B. J., Lin, Y.-F., von Messling, V., Jegerlehner, A., Tee, J. B. S., Chye, D. H., Wong, S. K. K., Ng, A. A. P., Lee, H. Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076571 · Cited by 31
Smoking cessation: present status and future perspectives
Caponnetto, P., Russo, C., & Polosa, R. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.005 · Cited by 30
An update on the use of laser technology in skin vaccination
Chen, X., Wang, J., Shah, D., & Wu, M. X. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.844070 · Cited by 29
Novel chimeric monoclonal antibodies that block fentanyl effects and alter fentanyl biodistribution in mice
Ban, B., Barrientos, R. C., Oertel, T., Komla, E., Whalen, C., Sopko, M. S., You, Y., Banerjee, P., Sulima, A., Jacobson, A. E., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1991552 · Cited by 27
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice
Zou, Y., Sonderegger, I., Lipowsky, G., Jennings, G. T., Schmitz, N., Landi, M., Köpf, M., & Bachmann, M. F. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.02.048 · Cited by 28
Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions
Cornish, K. E., de Villiers, S. H. L., Pravetoni, M., & Pentel, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082557 · Cited by 28
Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
Alves, E. R., Salman, A. M., Leoratti, F. M. S., López‐Camacho, C., Viveros‐Sandoval, M. E., Lall, A., El-Turabi, A., Bachmann, M. F., Hill, A. V. S., Janse, C. J., et al. (2017) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00501-16 · Cited by 28
Peptide-free Synthetic Nicotine Vaccine Candidates with α-Galactosylceramide as Adjuvant
Chen, X.-Z., Zhang, R., Wang, X., Yin, X., Wang, J., Wang, Y., Liu, X., Du, J., Liu, Z., & Guo, J. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01095 · Cited by 28
Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence
Hall, W., & GARTNER, C. E. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328345922b · Cited by 29
Interventions to prevent periodontal disease in tobacco‐, alcohol‐, and drug‐dependent individuals
Kumar, P. (2020) · Periodontology 2000 · doi:10.1111/prd.12333 · Cited by 26
Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®)
Heath, M. D., Mohsen, M. O., de Kam, P., Velazquez, T. L. C., Hewings, S. J., Kramer, M. F., Kündig, T. M., Bachmann, M. F., & Skinner, M. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594911 · Cited by 26
RNA‐Directed Packaging of Enzymes within Virus‐like Particles
Fiedler, J. D., Brown, S. D., Lau, J. L., & Finn, M. G. (2010) · Angewandte Chemie · doi:10.1002/ange.201005243 · Cited by 26
Production and characterization of novel ssRNA bacteriophage virus-like particles from metagenomic sequencing data
Lieknina, I., Kalnins, G., Akopjana, I., Bogans, J., Sisovs, M., Jansons, J., Rumnieks, J., & Tārs, K. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0497-8 · Cited by 23
Immunotherapies for the Treatment of Drug Addiction
Hossain, M. K., Davidson, M., Kypreos, E., Feehan, J., Muir, J. A., Nurgali, K., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10111778 · Cited by 27
Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse—Methamphetamine and 3,4‐methylenedioxymethamphetamine
Celikel, R., Peterson, E. C., Owens, S. M., & Varughese, K. I. (2009) · Protein Science · doi:10.1002/pro.244 · Cited by 23
Current status of immunotherapies for addiction
Xu, A., & Kosten, T. R. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14329 · Cited by 23
Vaccine development against methamphetamine drug addiction
Hossain, M. K., Hassanzadeganroudsari, M., Nurgali, K., & Apostolopoulos, V. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1857738 · Cited by 23
Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide
Mogus, A. T., Liu, L., Jia, M., Ajayi, D. T., Xu, K. Y., Kong, R., Huang, J., Yu, J., Program, V. P., Kwong, P. D., et al. (2020) · Vaccines · doi:10.3390/vaccines8040765 · Cited by 22
RNA Phage VLP-Based Vaccine Platforms
Peabody, D. S., Peabody, J., Bradfute, S. B., & Chackerian, B. (2021) · Pharmaceuticals · doi:10.3390/ph14080764 · Cited by 22
Proof of concept for a single-dose Group B Streptococcus vaccine based on capsular polysaccharide conjugated to Qβ virus-like particles
Carboni, F., Cozzi, R., Romagnoli, G., Tuscano, G., Balocchi, C., Buffi, G., Bodini, M., Brettoni, C., Giusti, F., Marchi, S., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00744-5 · Cited by 22
Paradox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines
Hu, Y. Y., Zhao, Z., Harmon, T. M., Pentel, P. R., Ehrich, M. F., & Zhang, C. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.08.015 · Cited by 22
Investigations of Enantiopure Nicotine Haptens Using an Adjuvanting Carrier in Anti-Nicotine Vaccine Development
Jacob, N. T., Lockner, J. W., Schlosburg, J. E., Ellis, B. A., Eubanks, L. M., & Janda, K. D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01676 · Cited by 21
Suppression of Nicotine-Induced Pathophysiology by an Adenovirus Hexon-Based Antinicotine Vaccine
Rosenberg, J. B., De, B. P., Hicks, M. J., Janda, K. D., Kaminsky, S. M., Worgall, S., & Crystal, R. G. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.245 · Cited by 21
Probing the protective effects of a conformationally constrained nicotine vaccine
Moreno, A. Y., Azar, M. R., Koob, G. F., & Janda, K. D. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.064 · Cited by 21
Nonpharmacological smoking cessation interventions in clinical practice
Cornuz, J., & Willi, C. (2008) · European Respiratory Review · doi:10.1183/09059180.00011003 · Cited by 21
Vaccines to Treat Substance Use Disorders: Current Status and Future Directions
Lu, T., Li, X., Zheng, W., Kuang, C., Wu, B., Liu, X., Xue, Y.-X., Shi, J., Lü, L., & Han, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010084 · Cited by 20
Smoking Cessation and Environmental Hygiene
Pirozzi, C., & Scholand, M. B. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.014 · Cited by 20
Vaccines as Immunotherapies for Substance Use Disorders
Kosten, T. R. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230828 · Cited by 19
Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines
Link, A., & Bachmann, M. F. (2010) · Immunotherapy · doi:10.2217/imt.10.30 · Cited by 19
A Glycolipid-Peptide-Hapten Tricomponent Conjugate Vaccine Generates Durable Antihapten Antibody Responses in Mice
Pankhurst, T. E., Montgomerie, I., Marshall, A. J., Draper, S. L., Bilbrough, T., Button, K. R., Palmer, O. R., Hermans, I. F., Painter, G. F., Connor, L. M., et al. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00214 · Cited by 18
Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity
Raleigh, M. D., Accetturo, C., & Pravetoni, M. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000014 · Cited by 18
Structural Analysis of an Antigen Chemically Coupled on Virus‐Like Particles in Vaccine Formulation
Jaudzems, K., Kirsteina, A., Schubeis, T., Casano, G., Ouari, O., Bogans, J., Kazāks, A., Tārs, K., Lesage, A., & Pintacuda, G. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202013189 · Cited by 18
Current Trends and Perspectives in the Immune Therapy for Substance Use Disorders
Vasiliu, O. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.882491 · Cited by 18
Hapten Optimization for Cocaine Vaccine with Improved Cocaine Recognition
Ramakrishnan, M., Kinsey, B. M., Singh, R. A. K., Kosten, T. R., & Orson, F. M. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12326 · Cited by 18
Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins
Zhao, Z., Hu, Y. Y., Harmon, T. M., Pentel, P. R., Ehrich, M. F., & Zhang, C. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.04.016 · Cited by 19
Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation
Baruffaldi, F., Raleigh, M. D., King, S. J., Roslawski, M. J., Birnbaum, A. K., Haßler, C., Carroll, F. I., Runyon, S. P., Winston, S., Pentel, P. R., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01296 · Cited by 18
Novel Pharmacological Approaches to Drug Abuse Treatment
Edens, E. L., Massa, A. A., & Petrakis, I. L. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_29 · Cited by 18
Viral protein-based nanoparticles (part 2): Pharmaceutical applications
Mellid-Carballal, R., Gutierrez-Gutierrez, S., Rivas, C., & García-Fuentes, M. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106558 · Cited by 17
Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction
Hossain, M. K., Hassanzadeganroudsari, M., Kypreos, E., Feehan, J., & Apostolopoulos, V. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1927725 · Cited by 17
The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats
Pentel, P. R., Raleigh, M. D., LeSage, M. G., Thisted, T., Horrigan, S. K., Biesová, Z., & Kalnik, M. W. (2018) · BMC Biotechnology · doi:10.1186/s12896-018-0457-7 · Cited by 17
Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response
Ning, W., Sheng, Y., Song, Y., Xu, H., Zhang, J., & Wang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1504124 · Cited by 16
Virus like particles: fundamental concepts, biological interactions, and clinical applications
Benjamin, C., Brohlin, O. R., Shahrivarkevishahi, A., & Gassensmith, J. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816662-8.00011-4 · Cited by 17
Next-generation viral nanoparticles for targeted delivery of therapeutics: Fundamentals, methods, biomedical applications, and challenges
Tan, J. S., Ali, M. N. B. J., Gan, B. K., & Tan, W. S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2228202 · Cited by 17
The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence
Laudenbach, M., Tucker, A. M., Runyon, S. P., Carroll, F. I., & Pravetoni, M. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.015 · Cited by 16
Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes
Phares, T. W., May, A. D., Genito, C. J., Hoyt, N. A., Khan, F. A., Porter, M. D., DeBot, M., Waters, N. C., Saudan, P., & Dutta, S. (2017) · Malaria Journal · doi:10.1186/s12936-017-1766-3 · Cited by 16
Broadly Neutralizing Synthetic Cannabinoid Vaccines
Lin, M., Lee, J. C., Blake, S., Ellis, B. A., Eubanks, L. M., & Janda, K. D. (2020) · JACS Au · doi:10.1021/jacsau.0c00057 · Cited by 16
Immunopharmacotherapeutic advancements in addressing methamphetamine abuse
Lee, J. C., & Janda, K. D. (2020) · RSC Chemical Biology · doi:10.1039/d0cb00165a · Cited by 16
Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge
Powers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00347 · Cited by 15
Insights into scFv:drug binding using the molecular dynamics simulation and free energy calculation
Hu, G., Zhang, Q., & Chen, L. Y. (2010) · Journal of Molecular Modeling · doi:10.1007/s00894-010-0892-4 · Cited by 15
Vaccines against Drug Abuse—Are We There Yet?
Bloom, B. T., & Bushell, M. (2022) · Vaccines · doi:10.3390/vaccines10060860 · Cited by 15
Engineered Biological Entities for Drug Delivery and Gene Therapy
Domingo‐Espín, J., Unzueta, U., Saccardo, P., Rodríguez‐Carmona, E., Corchero, J. L., Vázquez, E., & Ferrer‐Miralles, N. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-416020-0.00006-1 · Cited by 17
Different Binding Modes of Free and Carrier-Protein-Coupled Nicotine in a Human Monoclonal Antibody
Tārs, K., Koteloviča, S., Lipowsky, G., Bauer, M., Beerli, R. R., Bachmann, M. F., & Maurer, P. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.10.042 · Cited by 15
A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans
Saylor, K., & Zhang, C. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.07.017 · Cited by 14
Nicotine vaccines: Will smokers take a shot at quitting?
Leader, A. E., Lerman, C., & Cappella, J. N. (2010) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq015 · Cited by 13
Virus‐like particle preparation is improved by control over capsomere‐DNA interactions during chromatographic purification
Gerstweiler, L., Bi, J., & Middelberg, A. P. J. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27687 · Cited by 13
Immunotherapeutic strategies for treating opioid use disorder and overdose
Luba, R. R., Martinez, S., Jones, J. D., Pravetoni, M., & Comer, S. D. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2173062 · Cited by 13
Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines’ immunogenicity
Scendoni, R., Bury, E., Ribeiro, I. L. A., Cameriere, R., & Cingolani, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2140552 · Cited by 13
Viruses and Virus-Like Particles in Biotechnology
Roldão, A., Silva, A. C., Mellado, M. C. M., Alves, P. M., & Carrondo, M. J. T. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-088504-9.00072-6 · Cited by 13
Yeast-Expressed Bacteriophage-Like Particles for the Packaging of Nanomaterials
Freivalds, J., Koteloviča, S., Voronkova, T., Ose, V., Tārs, K., & Kazāks, A. (2013) · Molecular Biotechnology · doi:10.1007/s12033-013-9686-0 · Cited by 12
Immunogenicity of a peptide‐based anti‐IgE conjugate vaccine in non‐human primates
Weeratna, R. D., Chikh, G., Zhang, L., Fraser, J. D., Thorn, J. M., Merson, J. R., McCluskie, M. J., CHAMPION, B. R., & Davis, H. L. (2016) · Immunity Inflammation and Disease · doi:10.1002/iid3.98 · Cited by 12
Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)
Fraleigh, N. L., Boudreau, J., Bhardwaj, N., Eng, N. F., Murad, Y. M., Lafrenie, R. M., Acevedo, R., Oliva, R., Díaz‐Mitoma, F., & Le, H. (2016) · Heliyon · doi:10.1016/j.heliyon.2016.e00147 · Cited by 12
Immunogenicity and Immunodominance in Antibody Responses
Vogel, M., & Bachmann, M. F. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_160 · Cited by 12
Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain
Sharma, G., & Vijayaraghavan, S. (2008) · Substance Abuse Research and Treatment · doi:10.1177/117822180800100005 · Cited by 16
Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products
Salmikangas, P., Flory, E., Reinhardt, J., Hinz, T., & Mačiulaitis, R. (2009) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-009-0991-5 · Cited by 11
Exploring the Landscape of the PP7 Virus-like Particle for Peptide Display
Keshavarz‐Joud, P., Zhao, L., Bobe, D., Hernández, C., Kopylov, M., Yen, L. Y., Djeddar, N., Thompson, B., Connors, C., Gibson, G. C., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c06178 · Cited by 10
Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity
Gradinati, V., Baruffaldi, F., Abbaraju, S., Laudenbach, M., Amin, R., Gilger, B. C., Velagaleti, P., & Pravetoni, M. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.027 · Cited by 10
Intranasal delivery of a nicotine vaccine candidate induces antibodies in mouse blood and lung mucosal secretions that specifically neutralize nicotine
Alzhrani, R. F., Xu, H., Valdes, S. A., & Cui, Z. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1820033 · Cited by 10
Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
Raleigh, M. D., Beltraminelli, N., Fallot, S., LeSage, M. G., Saykao, A. T., Pentel, P. R., Fuller, S., Thisted, T., Biesova, Z., Horrigan, S. K., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254247 · Cited by 10
Calix[n]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine
Neto, L. D. S., Maia, A. F. D. S., Godin, A. M., Augusto, P. S. D. A., Pereira, R. L. G., Caligiorne, S. M., Alves, R. B., Fernandes, S. O. A., Cardoso, V. N., Goulart, G. A. C., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.09.003 · Cited by 10
A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects
Celik, M. A., & Fuehrlein, B. (2022) · ImmunoTargets and Therapy · doi:10.2147/itt.s370435 · Cited by 10
Anti-addiction vaccines
Shen, X. Y., Orson, F. M., & Kosten, T. R. (2011) · F1000 Medicine Reports · doi:10.3410/m3-20 · Cited by 10
Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists
Yang, F., & Kosten, T. R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5176-9 · Cited by 9
Update on smoking cessation therapies
Glynn, D. A., Cryan, J. F., Kent, P., Flynn, R. A., & Kennedy, M. P. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0022-9 · Cited by 9
Substructure-Specific Antibodies Against Fentanyl Derivatives
Chapman, A. P., Xu, M., Schroeder, M., Goldstein, J. M., Chida, A. S., Lee, J. R., Tang, X., Wharton, R. E., & Finn, M. G. (2025) · ACS Nano · doi:10.1021/acsnano.4c14369 · Cited by 8
Passive immunization against nicotine attenuates somatic nicotine withdrawal syndrome in the rat
Malin, D. H., Moon, W. D., Goyarzu, P., Magallanes, N., Blair, M. B., Alexander, M. R., McDavid, L., Spurgeon, J. L., Ennifar, S., & Fattom, A. (2010) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq021 · Cited by 8
Smoking Cessation
Miranda, J. A. R., Ruiz, C. A. J., & Rebollo, J. C. S. (2013) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0b013e31828fda4c · Cited by 8
Emerging drugs for the treatment of tobacco dependence
Ebbert, J. O. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802623874 · Cited by 8
Practical Considerations for the Development of Vaccines Against Drugs of Abuse
Torres, O. B., Alving, C. R., Jacobson, A. E., Rice, K. C., & Matyas, G. R. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_20 · Cited by 8
Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine
Zhao, Z., Hu, Y. Y., Harmon, T. M., Pentel, P. R., Ehrich, M. F., & Zhang, C. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00279 · Cited by 8
Nicotine Conjugate Vaccine as a Novel Approach to Smoking Cessation
Ottney, A. R. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.7.703 · Cited by 7
Vaccination against smoking: an annotated agenda for debate. A review of scientific journals, 2001–13
Wolters, A., de Wert, G. M. W. R., van Schayck, O. C. P., & Horstman, K. (2014) · Addiction · doi:10.1111/add.12572 · Cited by 7
Scientific overview: 2013 BBC plenary symposium on tobacco addiction
Biasi, M. D., McLaughlin, I., Perez, E. E., Crooks, P. A., Dwoskin, L. P., Bardo, M. T., Pentel, P. R., & Hatsukami, D. K. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.05.013 · Cited by 7
Preventing Sin: The Ethics of Vaccines Against Smoking
Lieber, S. R., & Millum, J. (2013) · The Hastings Center Report · doi:10.1002/hast.159 · Cited by 7
Current status of vaccines in psychiatry—A narrative review
Kuppili, P. P., Manohar, H., & Menon, V. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.02.004 · Cited by 7
Invisible work, actors, and knowledge: An analysis of a clinical trial for a vaccine to stop smoking
Wolters, A., de Wert, G. M. W. R., van Schayck, O. C. P., & Horstman, K. (2018) · BioSocieties · doi:10.1057/s41292-018-0136-x · Cited by 7

Authors: Cornuz, J., Zwahlen, S., Jungi, W. F., Osterwalder, J., Klingler, K., van Melle, G., Bangala, Y., Guessous, I., Müller, P., Willers, J., Maurer, P., Bachmann, M. F., & Cerny, T.
Affiliations: Centre Hospitalier Universitaire Vaudois (CH)
Kantonsspital St. Gallen (CH)
Corresponding author: Cornuz, Jacques
ORCID: Cornuz, Jacques
Osterwalder, Joseph
Guessous, Idris
Müller, Philipp
Bachmann, Martin F.
Venue: PLoS ONE
Publisher: Public Library of Science (PLoS)
Published: 2008-06-25
Volume: 3
Issue: 6
Pages: e2547
ISSN: 1932-6203 (ISSN-L)
DOI: 10.1371/journal.pone.0002547
PMC: PMC2432028
OpenAlex: W2069871552
Cited by: 281
References: 28
Citations by year: 2026: 9 · 2025: 7 · 2024: 5 · 2023: 10 · 2022: 9 · 2021: 11 · 2020: 15 · 2019: 11 · 2018: 13 · 2017: 21 · 2016: 18 · 2015: 25 · 2014: 14 · 2013: 27 · 2012: 19
FWCI: 15.16
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (unspecified)
Locations: PLoS ONE (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Figshare (submittedVersion, cc-by)
IRIS (submittedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords: nicotine vaccine, smoking cessation, nicotine dependence, tobacco dependence, antibody response, immunotherapy, continuous abstinence, behavioral counseling, vaccine safety
MeSH terms: Adult, Antibody Formation, Double-Blind Method, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Nicotine, Placebos, Vaccines, Smoking Cessation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks